130286-84-9

Basic information

• Product Name: N,N-diethyl-3,4-difluorobenzamide
• Synonyms: N,N-diethyl-3,4-difluorobenzamide
• CAS NO: 130286-84-9
• Molecular Weight: 213.227
• Mol File: 130286-84-9.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N,N-diethyl-3,4-difluorobenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-diethyl-3,4-difluorobenzamide(130286-84-9)
• EPA Substance Registry System: N,N-diethyl-3,4-difluorobenzamide(130286-84-9)

Safety Data

• Hazardous Substances Data: 130286-84-9(Hazardous Substances Data)

Upstream product

• 76903-88-3 3,4-difluorobenzoyl chloride 
• 109-89-7 diethylamine 
• 455-86-7 3,4-Difluorobenzoic acid 

Downstream Products

• 1985607-83-7 7,8-difluoro-6,11-dihydrodibenzo[b,e]thiazepine-11-ol 
• 2136287-66-4 7,8-difluoro-6,11-dihydrodibenzo[b,e]thiazepin-11-one 
• 2136287-65-3 3,4-difluoro-2-((phenylthio)methyl)benzoic acid 
• 149947-15-9 3-bromo-2-fluorobenzaldehyde 

Relevant articles and documents

Reactivity of (poly)fluorobenzamides in palladium-catalysed direct arylations

The influence of fluoro-substituents on secondary and tertiary benzamides on the regioselectivity of palladium-catalysed direct arylations was studied. With most (poly)fluoro-substituted tertiary benzamides, the arylations proceed very regioselectively at ortho-positions of the fluoro substituents using 1 mol% of air-stable palladium catalysts and PivOK/DMA as the reaction conditions. With the 3,5-difluoro-substituted secondary benzamides, quite regioselective arylations at C4-positions were observed. For these reactions, a variety of substituents on the aryl bromide, such as ester, propionyl, acetyl, formyl, nitro, nitrile, trifluoromethyl, chloro, fluoro or methyl, was tolerated. These results reveal that under our reaction conditions, fluoro substituents act as better directing groups than amides in the palladium-catalysed direct arylations.

ORGANIC COMPOUNDS

The present invention provides a compound of formula (I):said compound is inhibitor of aldosterone synthase, and thus can be employed for the treatment of a disorder or disease mediated by aldosterone synthase. Accordingly, the compound of formula I can be used in treatment of hypokalemia, hypertension, congestive heart failure, renal failure, in particular, chronic renal failure, restenosis, atherosclerosis, syndrome X, obesity, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, cardiac fibrosis and remodeling following hypertension and endothelial dysfunction. Finally, the present invention also provides a pharmaceutical composition.